121 related articles for article (PubMed ID: 31748210)
1. A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.
Riddle MC
Diabetes Care; 2019 Dec; 42(12):2161-2163. PubMed ID: 31748210
[No Abstract] [Full Text] [Related]
2. Is it time to ban sulfonylureas?
Ceriello A
J Diabetes; 2020 Nov; 12(11):848-850. PubMed ID: 32767650
[No Abstract] [Full Text] [Related]
3. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
4. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
5. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
6. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
7. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
8. [Clinical efficacy of glimepiride].
Kaneko T; Sakamoto N
Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
[No Abstract] [Full Text] [Related]
9. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion.
Adachi H; Yanai H
Diabetes Metab; 2015 Apr; 41(2):176-7. PubMed ID: 25559655
[No Abstract] [Full Text] [Related]
10. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride.
Noakes R
Australas J Dermatol; 2003 Nov; 44(4):302-3. PubMed ID: 14616504
[No Abstract] [Full Text] [Related]
11. Rosiglitazone and cardiotoxicity--weighing the evidence.
Nathan DM
N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161
[No Abstract] [Full Text] [Related]
12. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
13. Sulfonylurea treatment in type 2 diabetes.
Bester K; Ton J; Korownyk C
Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607
[No Abstract] [Full Text] [Related]
14. Oral hypoglycaemic agents.
Borthwick LJ; Stowers JM
Practitioner; 1979 Mar; 222(1329):358-66. PubMed ID: 450836
[No Abstract] [Full Text] [Related]
15. Cardiovascular effects of diabetes drugs: emerging from the dark ages.
Nissen SE
Ann Intern Med; 2012 Nov; 157(9):671-2. PubMed ID: 23128866
[No Abstract] [Full Text] [Related]
16. Does mortality risk vary among sulfonylureas?
Pantalone KM
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):6-7. PubMed ID: 25466240
[No Abstract] [Full Text] [Related]
17. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
19. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
20. [Glimepiride--an oral antidiabetic agent].
Becić F; Kapić E; Becić E
Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]